Our vision: Life-changing outcomes. Uncompromising safety.
Our vision: Life-changing outcomes. Uncompromising safety.
At Quell, we see a future where people living with refractory autoimmune disease can achieve safe, life-changing and durable resolution of their disease from a single, outpatient dose of engineered nTregs.
Our Ambition
A different kind of Cell Therapy company
Simple. Scalable. Designed to serve many patients.
Cell therapy can deliver transformational outcomes, but first-generation therapies were built for life-threatening cancers treated in hospital and on platforms that are hard to scale. Autoimmune disease affects millions of people who need therapies that are effective, well tolerated and accessible outside hospital.
Quell is designing engineered nTreg therapies specifically for complex autoimmunity.
Large Markets
One product, many diseases
Developing pipeline-in-a-product candidates, designed to treat multiple complex autoimmune diseases.
Simple Access
Outpatient treatment model
Designing therapies to avoid lymphodepletion and toxicities such as CRS, LICATS so they could be given in the outpatient setting.
Scalable Manufacturing
Built to scale
Manufacturing built to scale from the outset, with a clear roadmap to automation and lower costs.
Our Team
A visionary team, passionately committed to delivering Quell's mission
Quell’s seasoned leadership team is dedicated to the delivery of transformative therapies to patients. Their extensive experience across all aspects of cell therapy development ensures continued leadership and innovation in the engineered Treg field.
Our Partners
Partnering is in our DNA
We work with leading biopharma, clinical, academic and manufacturing partners who share our goal of bringing transformational nTreg therapies to patients.
Biopharma
In the spirit of ‘partnering with the best’, Quell is always looking for world-leading pharma partners to collaborate with, sharing a clear goal of bringing together complimentary skill sets and knowledge bases, which together help us move the field forward, develop better therapeutics and change patients lives.
Clinical & academic
Our CHILL study is led by world-leading rheumatology investigators across the UK, Germany and Spain, including the Kennedy Institute of Rheumatology, Friedrich-Alexander University Erlangen–Nuremberg, University of Leeds, University of Newcastle and Heinrich-Heine-University Düsseldorf. We also partner with scientific and clinical collaborators at King’s College London, UCL, UHN and Hannover Medical School.
Manufacturing & automation
Every patient with a refractory autoimmune condition should have the option of durable disease control. So, while we develop engineered nTreg therapies, we are also solving cell therapy’s scalability, cost and access challenges. We partner with the best manufacturing and automation partners in the field, who share our goals and values.
Interested in partnering?
Contact Business Development
Investors
Our Partners
At Quell, we are passionate about our mission for bringing life-changing immune-therapies of the future, into our world of today – We are pleased to be partnered with investors who collectively share our passion and our values.
© 2026 Quell Therapeutics